Ultromics Introduces Novel Cardiac Amyloidosis Screening Device for Heart Failure
Ultromics has introduced the EchoGo® Amyloidosis, an AI-powered software medical device designed to enhance the early detection of Cardiac Amyloidosis, a frequently underdiagnosed cause of heart failure.
As part of Ultromics’ EchoGo® platform, this new device complements the already commercialised EchoGo® Heart Failure solution.
EchoGo® Amyloidosis becomes the first FDA-cleared, software-only medical device capable of detecting Cardiac Amyloidosis through echocardiography. It requires just one routine echocardiographic clip and significantly less clinical data than current methods to identify the disease.
Echocardiography is a key tool for assessing cardiac structure and function and plays a vital role in disease detection and monitoring. Yet, certain conditions, like Cardiac Amyloidosis, can be difficult for even expert clinicians to detect on an echocardiogram.
EchoGo® Amyloidosis simplifies the process by utilising only a single apical 4-chamber image to identify the disease, ensuring earlier diagnosis and timely access to treatment for patients.
This capability to automatically flag potential Cardiac Amyloidosis with minimal clinical data offers practical advantages, especially for clinical centres that may lack the resources, time, or expertise to detect the disease from the echocardiogram, which often presents with ambiguous features.
US Food and Drug Administration has received (FDA) clearance as EchoGo® Amyloidosis as the first device for the early detection of cardiac amyloidosis.